Loxo gains on additional efficacy data for LOXO-101

Loxo Oncology Inc. (NASDAQ:LOXO) jumped $4.43 (19%) to $27.68 on Monday after reporting that LOXO-101 produced an objective response in three solid tumor patients harboring a TRK fusion in an ongoing Phase I trial. The three patients with soft tissue sarcoma, gastrointestinal stromal tumor (GIST) or mammary analogue secretory cancer of the salivary glands (MASC) all were refractory to standard therapy.

LOXO-101 is a selective small molecule inhibitor of tropomyosin receptor kinase (TRK) family, which includes neurotrophic tyrosine kinase receptor 1 ( TrkA; NTRK1), TrkB and TrkC. ...